Low-dose hormone replacement therapy: Effects on bone

Climacteric

Volumn 5, Issue 2, 2002, Pages 135-139

  Gambacciani, M ^a   Monteleone, P ^a   Genazzani, A R ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Low dose hormone replacement therapy; Menopause; Osteoporosis

Indexed keywords

CALCIUM; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; MEDROXYPROGESTERONE ACETATE; RALOXIFENE; TIBOLONE; VITAMIN D;

BONE ATROPHY; BONE DISEASE; BONE TURNOVER; BREAKTHROUGH BLEEDING; CALCIUM INTAKE; CLIMACTERIUM; DIET SUPPLEMENTATION; DOSE CALCULATION; DOSE RESPONSE; ELDERLY CARE; ENDOMETRIUM; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SYMPTOM; UTERUS BLEEDING; DRUG ADMINISTRATION; WOMEN'S HEALTH;

DRUG ADMINISTRATION SCHEDULE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; WOMEN'S HEALTH;

EID: 0036001262     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/cmt.5.2.135.139     Document Type: Review

References (35)

1. The minimum effective dose of estrogen for prevention of post-menopausal bone loss
2. Quantitative computed tomography of vertebral spongiosa: A sensitive method for detecting early bone loss after oophorectomy
3. Dose-response evaluation of cyclic estrogen/gestagen in postmenopausal women: Placebo-controlled trial of its gynaecologic and metabolic actions
4. Long-term estrogen replacement therapy prevents bone loss and fractures
5. Long-term prevention of postmenopausal osteoporosis by estrogen
6. Estrogen therapy in the prevention and management of osteoporosis
7. Hormone therapy to prevent disease and prolong life in postmenopausal women
8. Hormone replacement therapy and the risk of hip fracture: Population based case-control study
9. Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss
10. Effects of transdermal estradiol administration on bone mass and bone metabolism in early postmenopausal women
11. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium
12. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: A 2-year prospective study
13. Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages
14. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial
15. Impact of adding medroxyprogesterone acetate (MPA) to multiple doses of conjugated equine estrogens (CEE) on bone density in postmenopausal women
16. Effect of progestin therapy on cortical and trabecular bone: Comparison with estrogen
17. A combination of low doses of 17β-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women
18. Calcium potentiates the effect of estrogen and calcitonin on bone mass: Review and analysis
19. Low dose estrogen and calcium have an additive effect on bone resorption in older women
20. Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women
21. Low-dosage micronized 17β-estradiol prevents bone loss in postmenopausal women
22. Tibolone: Prevention of bone loss in late postmenopausal women
23. Prevention of bone loss with tibolone in postmenopausal women: Results of two randomized, double-blind placebo-controlled, dose-finding studies
24. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding
25. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism
26. Effects of 2 years of hormone replacement upon bone mass, serum lipids and lipoproteins
27. Low-dose esterified estrogen therapy: Effects on bone, plasma estradiol concentrations, endometrium, and lipid levels
28. Long-term continuous-combined hormone replacement therapy in the prevention of postmenopausal bone loss; a comparison of high- and low-dose estrogen-progestin regimens
29. Effect of low-dose continuous estrogen and progestin therapy with calcium and vitamin D on bone in elderly women
30. 17β-estradiol (1 mg/day) continuously combined wuth dydrogesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women
31. Effects of low-dose continuous-combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women
32. Markers of bone turnover for the prediction of fracture risk
33. Pre-existing fractures and bone mass predict vertebral fracture incidence in women
34. Long-term fracture prediction by bone mineral assessed at different skeletal sites
35. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial